Recent insider selling of Avanos Medical stock, particularly by Senior VP Michael Greiner, is concerning. Insiders' lack of significant ownership and their share selling could deter potential investors.
Unresolved challenges may be indicated by weak growth and share price performance. The market's focus is likely on revenue due to the company's lack of profits. Accelerated revenue growth or profits could attract more interest in the stock.
Analysts predict a below-average future growth rate for Avanos Medical despite its high P/E ratio. This warns of a possible risk for investors, who might pay a premium not supported by the earnings outlook.
Avanos Medical股票讨论区
利润表显示近两年盈利得益于营业费用的控制,主要是其它营业费用的减少。
2022年利息费用占营业利润的12%,负担略高。
2023Q1营收下滑2.9%,营业利润下滑70%至260万,净利润略亏。
目前看盈利数据还很有限,可以继续观察。
暂无评论